Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?


18:21 Uhr
ROUNDUP/Aktien Frankfurt Schluss: Dax wieder unter 13 000 Punkten

SHIRE PLC - Notice of Results

Mittwoch, 19.10.2016 16:05 von

PR Newswire

Shire to announce third quarter 2016 results

Dublin, IrelandOctober 19, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2016 earnings on Tuesday November 1, 2016.

Results press release will be issued at: 12:00 GMT / 08:00 EDT
Investor conference call time: 14:00 GMT / 10:00 EDT

Live conference call for investors:

Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial Officer will host the investor and analyst conference call at 10:00 EDT / 14:00 GMT.

The details of the conference call are as follows:

UK dial in: 0808 237 0030 or 020 3139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers:
Password/Conf ID: 42020034#
Live Webcast:


A replay of the presentation will be available for two weeks by phone and by webcast for three months.  Replay information can be found on the Investor Relations section of Shire’s website at

For further information please contact:

Investor Relations
Sarah Elton-Farr +44 1256 894157
Ian Karp +1 781 482 9018
Robert Coates +44 1256 894874

Notes to editors

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.